Bibliographic information

GuidelineWHO consolidated guidelines on tuberculosis: module 4: treatment and care
Year of Publication2025
Issuing InstitutionWorld Health Organization

Recommendation

Maintained

The use of fixed-dose combination (FDC) tablets is recommended over separate drug formulations in the treatment of patients with drug-susceptible TB

Recommended in favor

Conditional

Notes and Remarks

Subgroup considerations The reduced pill burden as a result of using FDCs may be especially valuable in patients with co-morbidities (notably HIV infection) and paediatric patients (who may have some difficulty in swallowing large amounts of medications). Patients with some specific medical conditions (e.g. intolerance to certain TB drugs, liver or renal function impairment) are likely to require individual medication dose adjustment which can be done only with separate drug formulations. Implementation considerations There are no specific implementation considerations as the use of FDC formulations is already widespread.

Also Featured In

This recommendation also appears in the following guidelines:

Originally Developed
Guideline

Guidelines for treatment of drug-susceptible tuberculosis and patient care

Year2017
InstitutionWorld Health Organization
Guideline

WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment.

Year2022
InstitutionWHO